Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots – a concise summary. Vascul Pharmacol. 2019; 113:1-8
Baglin TP, Cousins D, Keeling DM Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol. 2007; 136:26-29 https://doi.org/10.1111/j.1365-2141.2006.06379.x
Dovlatova N, Jakubowski J, Sugidachi A, Heptinstall S. The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thrombosis Haemost. 2008; 6:1153-1159
Lillis T, Ziakas A, Koskinas K Safety of dental extractions during uninterrupted single or dual antiplatelet treatment. Am J Cardiol. 2011; 108:964-967 https://doi.org/10.1016/j.amjcard.2011.05.029
Dinkova AS, Atanasov DT, Vladimirova-Kitova LG. Discontinuation of oral antiplatelet agents before dental extraction – necessity or myth?. Folia Med (Plovdiv). 2017; 59:336-343
Saez-Alcaide LM, Sola-Martin C, Molinero-Mourelle P Dental management in patients with antiplatelet therapy: a systematic review. J Clin Exp Dent. 2017; 9:e1044-e1050 https://doi.org/10.4317/jced.54079
Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006; 62:509-511
Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. J Am Coll Cardiol. 2003; 41:1633-1652
Coons J, Empey P. Drug metabolism in cardiovascular disease. In: Xie W (ed). San Diego, CA, USA: Elsevier; 2016
Abdullah WA, Khalil H. Dental extraction in patients on warfarin treatment. Clin Cosmet Investig Dent. 2014; 6:65-69 https://doi.org/10.2147/CCIDE.S68641
Costantinides F, Rizzo R, Pascazio L, Maglione M. Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. BMC Oral Health. 2016; 16 https://doi.org/10.1186/s12903-016-0170-7
Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 116:e191-195 https://doi.org/10.1016/j.oooo.2013.05.001
Mingarro-de-Leon A, Chaveli-Lopez B. Alternative to oral dicoumarin anticoagulants: considerations in dental care. J Clin Exp Dent. 2013; 5:e273-278 https://doi.org/10.4317/jced.51226
Tran A, Cheng-Lai A. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin. Cardiol Rev. 2011; 19:154-161
Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011; 62:41-57 https://doi.org/10.1146/annurev-med-062209-095159
Pollack CV, Reilly PA, van Ryn J Idarucizumab for dabigatran reversal—full cohort analysis. N Engl J Med. 2017; 377:431-441
Breik O, Cheng A, Sambrook P, Goss A. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J. 2014; 59:296-301 https://doi.org/10.1111/adj.12199
Levy JH, Key NS, Azran MS. Novel oral anticoagulants. Implications in the perioperative setting. Anesthesiology. 2010; 113:726-745
Connolly SJ, Ezekowitz MD, Yusuf S Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-1151 https://doi.org/10.1056/NEJMoa0905561
Eikelboom JW, Wallentin L, Connolly SJ Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123:2363-2372 https://doi.org/10.1161/CIRCULATIONAHA.110.004747
Davis C, Robertson C, Shivakumar S, Lee M. Implications of dabigatran, a direct thrombin inhibitor, for oral surgery practice. J Can Dent Assoc. 2013; 79
Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol. 2012; 11:1066-1081 https://doi.org/10.1016/S1474-4422(12)70258-2
Dentali F, Riva N, Crowther M Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012; 126:2381-2391 https://doi.org/10.1161/CIRCULATIONAHA.112.115410
Frost C, Nepal S, Wang J Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013; 76:776-786 https://doi.org/10.1111/bcp.12106
Curto A, Albaladejo A. Implications of apixaban for dental treatments. J Clin Exp Dent. 2016; 8:e611-e614 https://doi.org/10.4317/jced.53004
Hong C, Islam I. Anti-thrombotic therapy: implications for invasive outpatient procedures in dentistry. J Blood Disord Transfus. 2013; 4
Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017; 114:206-221 https://doi.org/10.1016/j.addr.2017.04.010
Fizazi K, Carducci M, Smith M Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377:813-822 https://doi.org/10.1016/S0140-6736(10)62344-6
Papapoulos S, Chapurlat R, Libanati C Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012; 27:694-701 https://doi.org/10.1002/jbmr.1479
Ruggiero SL, Dodson TB, Fantasia J American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014; 72:1938-1956
Yamazaki T, Yamori M, Ishizaki T Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012; 41:1397-1403 https://doi.org/10.1016/j.ijom.2012.06.020
Mehrotra B, Fantasia J, Ruggiero S. Outcomes of bisphosphonate-related osteonecrosis of the jaw—importance of staging and management guidelines: a large single institutional update. J Clin Oncol. 2008; 26:20526-20526
Ripamonti CI, Maniezzo M, Campa T Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009; 20:137-145 https://doi.org/10.1093/annonc/mdn526
Khan AA, Sandor GK, Dore E Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008; 35:1391-1397
Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. Drugs. 1994; 47:25-50
De Souza S, Bansal R, Galloway J. Managing patients with rheumatoid arthritis. BDJ Team. 2017; 4
Sollecito TP, Abt E, Lockhart PB The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: evidence-based clinical practice guideline for dental practitioners—a report of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015; 146:11-16.e18
The impact of drug therapy on minor oral surgery procedures Khadeeja Saleem Paras Ahmad Jawaad Ahmed Asif Mohmed Isaqali Karobari Tahir Yusuf Noorani Dental Update 2024 48:11, 707-709.
Authors
KhadeejaSaleem
BDS, MSc
Postgraduate student, Oral Medicine Unit; School of Dental Sciences, Universiti Sains Malaysia
Senior Lecturer, Conservative Dentistry Unit, School of Dental Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kota Bharu, Kelantan, Malaysia.
Some advanced and slightly more invasive treatments require the use of certain drugs before, during and after the treatment like local anesthetics, vasoconstrictors, anxiolytics, analgesics and antibiotics. All of these can possibly interact with medications a patient is already taking and can also interfere with the current dental treatment and create complications. This article aims to provide necessary information about commonly encountered systemic diseases and associated treating medications, their mechanism of action, possible complications and their management.
CPD/Clinical Relevance: This article discusses drugs that are used for treating various systemic conditions, but can have a harmful effect on minor oral surgery procedures.
Article
Minor oral surgical procedures are performed daily around the globe. These forms of minor oral surgery are not restricted to just removing impacted teeth or severely broken-down teeth, they also include apicectomy, biopsy, placement of dental implants, sinus lift and other procedures. These procedures impose a substantial risk of bleeding, dry socket, infection and bone necrosis. Every patient is at risk of developing a complication; however, the risk is increased in patients being treated for various systemic diseases. Table 1 describes the risk of common complications during or after dental procedures.
DMARD: disease-modifying anti-rheumatic drugs; INR: international normalized ratio; MRONJ: medication-related osteonecrosis of the jaw; TT: thrombin time; PTT: partial thromboplastin time
This article gathers and analyses those drugs that are used for treating various systemic conditions, but can have a deleterious effect on minor oral surgery. Although these drugs are not prescribed by dentists, dentists will certainly encounter patients using a spectrum of drugs that are often novel, and post-dental treatment complications and management in such patients should be known to every dentist.
Register now to continue reading
Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:
